Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

BACKGROUND: Efficacy-safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab (ALI) and evolocumab (EVO), have previously been evaluated through controlled clinical trials with selective patient groups. Post-commercially, in 69 patients with heterozygous familial hyperc...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Joshua, Khan, Amir M, Jarmin, Michael, Goldenberg, Naila, Glueck, Charles J, Wang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525304/
https://www.ncbi.nlm.nih.gov/pubmed/28738813
http://dx.doi.org/10.1186/s12944-017-0493-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525304/
https://www.ncbi.nlm.nih.gov/pubmed/28738813
http://dx.doi.org/10.1186/s12944-017-0493-7

Ejemplares similares